Castleman’s disease (CD) is one of the reactive lymphadenopathies of undetermined cause. It is a rare clinical condition characterized by significant enlargement of deep or superficial lymph nodes, which in some cases may be accompanied by systemic symptoms and/or multi-system damage. In most cases, good results can be achieved after surgical removal of enlarged lymph nodes. Castleman’s disease is mainly characterized by significant enlargement of lymph nodes with or without systemic symptoms, and in severe cases, it may involve multiple systems.Castleman’s disease usually requires timely consultation with the Department of Infectious Diseases and other appropriate departments, and further investigations, such as bone marrow smear examination and pathological examination, to confirm the diagnosis, which needs to be differentiated from lymphoma and hemangio-immunoblastoid lymphadenopathy. The disease is divided into two categories: focal and multicenter. Treatment is based on surgical removal of the diseased lymph nodes. For multicentric CD with extensive lesions, only chemotherapy can be chosen, and chemotherapy is usually used to treat malignant lymphoma with combination chemotherapy regimens, such as: nitrogen mustard combined with vincristine, procarbazine, prednisone to form the MOPP regimen; or resection of the main lesions and local radiotherapy. If there is any discomfort, it is recommended to consult a doctor in time and carry out targeted treatment under the guidance of a professional doctor to clarify the cause of the disease, and do not be negligent so as not to delay the condition.